Core Insights - Hansoh Pharmaceutical Group Limited announced the approval of a fifth indication for Amelotex (Ametinib Mesylate Tablets), which is now indicated for first-line treatment in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][2] Group 1: Product Approval and Clinical Data - The approval is based on the AENEAS 2 Phase III clinical study, which demonstrated that Amelotex combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified [1] - The study included only Chinese patients, highlighting the efficacy and safety of the original EGFR-TKI in this demographic [1] Group 2: Product Background and Market Position - Amelotex is the first original third-generation EGFR-TKI in China, approved for five indications since its initial launch in March 2020 [2][3] - Previous indications include postoperative adjuvant therapy for EGFR mutation NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2] - The drug has established a strong clinical position in treating lung cancer in China, providing high-level evidence for its use [2] Group 3: Company Overview - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [4] - The company has a strong revenue stream from innovative drugs, with over 80% of its income derived from this segment, and has established a rich R&D pipeline [4] - Hansoh Pharmaceutical has been recognized as one of the top global pharmaceutical companies and is listed on the Hong Kong Stock Exchange under the stock code 03692.HK [4]

Group 1 - The core point of the news is that Hansoh Pharmaceutical announced the approval of a fifth indication for Amelot (Ametinib Mesylate Tablets) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval is based on the AENEAS2 Phase III clinical study, which demonstrated that Amelot combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified in the study, which included only Chinese patients [1] Group 2 - Since its initial approval in March 2020, Amelot has expanded from a single indication to five, with all previous indications included in the national medical insurance catalog, enhancing its clinical position and providing high-level evidence for the treatment of lung cancer in China [2] - The previously approved indications include postoperative adjuvant therapy for EGFR-mutant NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2]